Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients by Giani, T. et al.
1www.eurosurveillance.org
Surveillance and outbreak report 
Evolving beta-lactamase epidemiology in 
Enterobacteriaceae from Italian nationwide surveillance, 
October 2013: KPC-carbapenemase spreading among 
outpatients
T Giani 1 2 , A Antonelli 2 3 , M Caltagirone ⁴ , C Mauri ⁵ , J Nicchi ³ , F Arena ¹ , E Nucleo ⁴ , S Bracco ⁵ , A Pantosti ⁶ , The AMCLI-CoSA 
survey participants ⁷ , F Luzzaro ⁵ , L Pagani ⁴ , GM Rossolini 1 3 8 
1. Department of Medical Biotechnologies, University of Siena, Siena, Italy
2. These authors contributed equally to this work
3. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
4. Department of Clinical, Surgical, Diagnostic, and Paediatric Sciences, Section of Microbiology, University of Pavia, Pavia, Italy
5. Microbiology and Virology Unit, Department of Laboratory Medicine, A. Manzoni Hospital, Lecco, Italy
6. Department of Infectious, Parasitic and Immune-Mediated Diseases, Italian National Health Institute, Rome, Italy
7. The AMCLI-CoSA survey participants are listed at the end of the article
8. Clinical Microbiology, Virology and Serology Unit, Florence Careggi University Hospital, Florence, Italy
Correspondence: Gian Maria Rossolini (gianmaria.rossolini@unifi.it)
Citation style for this article: 
Giani T, Antonelli A, Caltagirone M, Mauri C, Nicchi J, Arena F, Nucleo E, Bracco S, Pantosti A, The AMCLI-CoSA survey participants, Luzzaro F, Pagani L, Rossolini 
GM. Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among 
outpatients. Euro Surveill. 2017;22(31):pii=30583. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.31.30583 
Article submitted on 28 June 2016 / accepted on 20 December 2016 / published on 03 August 2017
Extended-spectrum beta-lactamases (ESBLs), AmpC-
type beta-lactamases (ACBLs) and carbapenemases 
are among the most important resistance mecha-
nisms in Enterobacteriaceae. This study investi-
gated the presence of these resistance mechanisms 
in consecutive non-replicate isolates of Escherichia 
coli (n = 2,352), Klebsiella pneumoniae (n = 697), and 
Proteus mirabilis (n = 275) from an Italian nationwide 
cross-sectional survey carried out in October 2013. 
Overall, 15.3% of isolates were non-susceptible to 
extended-spectrum cephalosporins but suscepti-
ble to carbapenems (ESCR-carbaS), while 4.3% were 
also non-susceptible to carbapenems (ESCR-carbaR). 
ESCR-carbaS isolates were contributed by all three 
species, with higher proportions among isolates from 
inpatients (20.3%) but remarkable proportions also 
among those from outpatients (11.1%). Most ESCR-
carbaS isolates were ESBL-positive (90.5%), and most 
of them were contributed by E. coli carrying blaCTX-M 
group 1 genes. Acquired ACBLs were less common and 
mostly detected in P. mirabilis. ESCR-carbaR isolates 
were mostly contributed by K. pneumoniae (25.1% and 
7.7% among K. pneumoniae isolates from inpatients 
and outpatients, respectively), with blaKPC as the most 
common carbapenemase gene. Results showed an 
increasing trend for both ESBL and carbapenemase 
producers in comparison with previous Italian surveys, 
also among outpatients.
Introduction
Enterobacteriaceae are the most common cause of 
healthcare associated infections, and beta-lactams are 
among the most used antibiotics in clinical practice for 
treatment of these infections [1,2]. During the last dec-
ades, Enterobacteriaceae with decreased susceptibility 
to beta-lactams have been increasingly reported world-
wide, causing major problems [3-8].
The most important resistance mechanism to beta-lac-
tams in Enterobacteriaceae is the production of beta-
lactamases, and the most challenging enzymes of this 
family are the extended-spectrum beta-lactamases 
(ESBLs), the AmpC-type beta-lactamases (ACBLs), and 
the carbapenemases [9-12]. ESBLs are able to hydro-
lyse a wide range of beta-lactams, including penicillins, 
narrow- and extended-spectrum cephalosporins and 
monobactams, but not cephamycins and carbapenems. 
ESBLs are usually inhibited by conventional beta-lac-
tamase inhibitors. CTX-M-type ESBLs, which emerged 
in the late 1980s, and demonstrated a high ability to 
disseminate in clinical settings, rapidly reaching a pan-
demic diffusion. Nowadays they are the most preva-
lent plasmid-encoded ESBLs overall [13,14]. Acquired 
ACBLs can confer resistance to penicillins and to most 
cephalosporins (including cephamycins) but are poorly 
or not active against monobactams and the zwitteri-
onic oxyimino-cephalosporins, such as cefepime and 
cefpirome, and the carbapenems. ACBLs are gener-
ally less prevalent than ESBLs in Enterobacteriaceae 
but are nonetheless important for their contribution 
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to beta-lactam resistance, which can be extended 
also to carbapenems when ACBLs are overproduced in 
combination with an impermeability defect [10,15,16]. 
Carbapenemase production is the leading resistance 
mechanism to carbapenems in Enterobacteriaceae. 
Acquired carbapenemases of the KPC-, VIM-, NDM- and 
OXA-48-types are the most prevalent, although with a 
notable geographical variability [6,17-20].
In Italy, the most recent data from the European 
Antimicrobial Resistance Surveillance Network (EARS-
Net) reported very high proportions of resistance to 
extended-spectrum cephalosporins among Escherichia 
coli (30.1%) and Klebsiella pneumoniae (55.9%), and 
of resistance to carbapenems among K. pneumoniae 
(33.5%) [21]. However, the EARS-NET data neither cover 
other enterobacterial species nor describe the resist-
ance mechanisms.
This survey, promoted by the Committee for Study 
of Antibiotics (CoSA) of the Italian Society of Clinical 
Microbiologists (AMCLI), was carried out to provide an 
updated picture of the molecular epidemiology of ESBL- 
and carbapenemase-producing Enterobacteriaceae cir-
culating in Italy and to investigate, for the first time, 
the presence of ACBL producers on a nationwide scale.
Methods
Study design
Fourteen clinical microbiology laboratories from 13 
Italian cities participated in the study (Figure 1).
The laboratories were selected so as to provide a 
countrywide coverage by large laboratories associated 
with hospitals, representative of most Italian Regions. 
Twelve of the 14 laboratories had also been involved 
in the first Italian survey on carbapenemase-producing 
Enterobacteriaceae, carried out in 2011 [22]. The survey 
period was from 1 to 15 October 2013.
The laboratories consecutively collected all non-repli-
cate (only first isolate from a patient included) clinical 
isolates of E. coli, K. pneumoniae and Proteus mira-
bilis, from any site of infection, showing a minimum 
inhibitory concentration (MIC) > 1 mg/L for extended-
spectrum cephalosporins (ESC) (cefotaxime and/or cef-
triaxone and/or ceftazidime and/or cefepime), and/or 
for ertapenem. Participating laboratories determined 
MICs of ESC and ertapenem by the automated systems 
routinely used in the respective laboratory: either Vitek 
2 (bioMérieux, Marcy l’Etoile, France) or BD Phoenix 
(Becton, Dickinson and Co., New Jersey, United States 
(US)). The collected isolates were sent to reference lab-
oratories for confirmation of species identification and 
characterisation of the resistance mechanisms.
For each isolate, information on the type of clinical 
specimen and of patient (inpatient or outpatient) were 
provided. Isolates from patients from nursing homes or 
other long-term care facilities, and isolates from sur-
veillance specimens, were excluded. Each laboratory 
also provided information on the total number of non-
replicate clinical isolates of Enterobacteriaceae of the 
same species observed during the collection period 
from inpatients and outpatients.
Bacterial identification, antimicrobial 
susceptibility testing and phenotypic 
characterisation of resistance mechanisms
At the reference laboratories, identification of collected 
isolates was confirmed by MALDI-TOF mass spectrom-
etry (Vitek MS, bioMérieux), and susceptibility to ESC 
(cefotaxime, ceftazidime, cefepime), carbapenems 
(ertapenem, imipenem, and meropenem), aztreonam, 
aminoglycosides (amikacin and gentamicin), cipro-
floxacin, trimethoprim/sulfamethoxazole was deter-
mined by disc diffusion on Mueller-Hinton agar (for P. 
mirabilis imipenem was not tested) according to the 
European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) methodology [23]. MICs of tige-
cycline and colistin for carbapenemase producers 
were determined using reference broth microdilution 
Figure 1
Distribution of the centers participating in the survey, 
Italy, October 2013 (n=14)
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For each centre the presence of CTX-M extended-spectrum beta-
lactamase and carbapenemase genes is also indicated.
Centers listed as follows: 1-Milano; 2-Lecco; 3-Novara; 4-San 
Remo; 5-Bolzano; 6-Udine; 7-Modena Bg; 8-Modena Pc; 9-Firenze; 
10-Ancona; 11-Roma; 12-San Giovanni Rotondo; 13-Avellino; 
14-Cosenza.
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[24] with custom lyophilised plates (TREK Diagnostic 
Systems, Cleveland, Ohio, US). All results were inter-
preted according to the EUCAST breakpoints [25]. 
ESBL production was investigated using the double 
disk method testing the synergistic activity between 
amoxicillin-clavulanate and cefotaxime, ceftazidime, 
cefepime, and aztreonam [26].
Molecular characterisation of resistance genes
The presence of carbapenemase genes was investi-
gated by multiplex real time-PCR (mRT-PCR) target-
ing blaKPC-type,blaVIM-type, blaOXA-48-type and 
blaNDM-type genes, using primers and conditions 
reported in Table 1. The presence of blaCTX-M ESBL 
genes was investigated by a mRT-PCR, able to dis-
tinguish among different blaCTX-M-type variants of 
groups 1, 2, 8/25 and 9, using primers and condi-
tions reported in Table 1. The presence of ACBL genes 
was investigated by a multiplex PCR targeting genes 
encoding ACBLs, as described previously [27]. For E. 
coli, specific primers designed to distinguish between 
acquired and chromosomal ACBL genes were used [27]. 
The presence of mcr-1-like genes was investigated by a 
novel real time-PCR (Table 1).
Spectrophotometric assay for carbapenemase 
activity
In carbapenem non-susceptible isolates that tested 
negative for known carbapenemase genes, carbapen-
emase production was further investigated by meas-
uring the imipenem-hydrolysing specific activity in 
bacterial crude extracts as described previously [28], 
using a Cary 100 UV-Vis spectrophotometer (Varian, 
Walnut Creek, California, US).
Statistical analysis
Statistical evaluation of differences between resistance 
rates observed in this study and previous surveillance 
studies was carried out with the chi-squared test with 
Yates correction, using the Stata Statistical Software 
(release 13, College Station, Texas, US). Since the sur-
veillance studies were overall similar by design but 
there were a few sampling differences, which could act 
as confounding factors, the tests were treated rather 
as exploratory analyses, which may indicate trends.
Figure 2
Distribution of Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis isolates according to resistance phenotypes and 
genotypes, nationwide surveillance survey, Italy, October 2013 (n=652 isolates)
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resistant isolates
n=652
ESCR-carbaR n=144 
• E. coli n=14
• K. pneumoniae n=130
• P. mirabilis n=0
ACBL n=37
• E. coli n=12
• P. mirabilis n=25
ACBL-negative n=11
• E. coli n=5
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• P. mirabilis n=1
CARBA n=118
• E. coli n=5
• K. pneumoniae n=113 
ESBL n=460
• E. coli n=361
• K. pneumoniae n=60 
• P. mirabilis n=39
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• E. coli n=28
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• P. mirabilis n=39
ESBL negative n=48
• E. coli n=17
• K. pneumoniae n=5 
• P. mirabilis n=26
CARBA-negative n=26
• E. coli n=9
• K. pneumoniae n=17 
ESBL n=20
• E. coli n=7
• K. pneumoniae n=13
ACBL n=4
• E. coli n=2
• K. pneumoniae n=2
KPC n=110
• E. coli n=2
• K. pneumoniae n=108
OXA-48 n=5
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VIM n=3
• E. coli n=1
• K. pneumoniae n=2
ESCR-carbaS n=508 
• E. coli n=378 
• K. pneumoniae n=65
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ACBL: isolates producing acquired class C beta-lactamase; CARBA: carbapenemase producing isolates; E. coli: Escherichia coli; ESBL: isolates 
producing extended spectrum beta-lactamase; ESCR-carbaS: isolates non-susceptible to extended-spectrum cephalosporins but susceptible 
to carbapenems; ESCR-carbaR: isolates non-susceptible to extended-spectrum cephalosporins and non-susceptible to carbapenems; K. 
pneumoniae: Klebsiella pneumoniae; P. mirabilis: Proteus mirabilis.
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Results
Prevalence of Enterobacteriaceae with 
resistance mechanisms to extended-spectrum 
cephalosporins and/or carbapenems
During the study period, a total of 3,324 consecutive 
non-replicate clinical isolates of Enterobacteriaceae of 
the target species were isolated in the 14 laboratories 
participating in the survey, including 2,352 (70.7%) 
E. coli, 697 (21.0%) K. pneumoniae, and 275 (8.3%) P. 
mirabilis. Of these, 1,509 isolates (45.4%) were from 
inpatients and 1,815 (54.6%) from outpatients (Table 
2).
Overall, 508 isolates were confirmed to be non-
susceptible to ESC but susceptible to carbapenems 
(ESCR-carbaS phenotype), and 144 isolates to be 
non-susceptible to both ESC and carbapenems (ESCR-
carbaR). Isolates susceptible to ESC and non-suscepti-
ble to carbapenems were not detected.
The ESCR-carbaS phenotypes were contributed by 
all three species, with higher proportions among P. 
Table 1
Sequence of primers and probes used in nationwide surveillance survey of the molecular epidemiology of ESBL- and 
carbapenemase-producing Enterobacteriaceae, Italy, October 2013
Target Primer name Sequence (5’-3’)a Reference Positive control
OXA-48-like-rt-F GTAGCAAAGGAATGGCAAGAAA
[44] Escherichia coli ECBZ-1 (blaOXA-48) [45]
bla OXA-48-
like genes
OXA-48-like-rt-R GATGCGGGTAAAAATGCTTG
OXA-48-like-rt-P HEX-CTCTGGAATGAGAATAAGCAGCAAGG-BHQ-1
bla KPC 
genes
KPC-rt-F GATACCACGTTCCGTCTGG
[46] Klebsiella pneumoniae FIPP-1 (blaKPC-3) [47]
KPC-rt-R GCAGGTTCCGGTTTTGTCTC
KPC-rt-P FAM-AGCGGCAGCAGTTTGTTGATTG-BHQ-1
bla VIM 
genes
VIM-rt-F TGGTCTCATTGTCCGTGATG
[48] K. pneumoniae VA-416/02 (blaVIM-4) [49]VIM-rt-R CATGAAAGTGCGTGGAGA
VIM-rt-P ROX-AAGCAAATTGGACTTCCCGTAACGC-BHQ-2
bla NDM 
genes
blaNDM1_F CGCAACACAGCCTGACTTT
[50] E. coli CVB-1 (blaNDM-1) [51]blaNDM1_R TCGATCCCAACGGTGATATT
blaNDM1_P CY5-CAACTTTGGCCCGCTCAAGGTATTT-BHQ-3
bla CTX-M 
group 1 
genes
CTX-M-group-1_FW AAAAATCACTGCGCCAGTTC
[52] E. coli V460a (blaCTX-M-15), in-house 
controlCTX-M-group-1_REV AGCTTATTCATCGCCACGTT
CTX-M-group1-P HEX-TGGCGACGGCAACCGTCACGCTGTT-BHQ-1 This study
bla CTX-M 
group 2 
genes
CTX-M-group-2_FW CGACGCTACCCCTGCTATT
[52] E. coli C277a (blaCTX-M-2), in-house 
controlCTX-M-group-2_REV CCAGCGTCAGATTTTTCAGG
CTX-M-group2-P FAM-TATTGAGCGTGGGCTCGGTTCTGTCCAG-BHQ-1 This study
bla CTX-M 
group 
8/25 
genes
CTX-M-group-8/25_ 
FW CGATACCACCACGCCATTAG This study
E. coli M26a (blaCTX-M-8), in-house 
controlCTX-M-group-8/25_REV AACCCACGATGTGGGTAGC [52]
CTX-M-group8/25-P CY5-CCTGAATGCTGGCAGCGCCGGTG-BHQ-3 This study
bla CTX - M 
group 9 
genes
CTX-M-group-9_FW CAAAGAGAGTGCAACGGATG
[52]
E. coli V404a (blaCTX-M-14) [53]CTX-M-group-9_REV ATTGGAAAGCGTTCATCACC
CTX-M-group9-P ROX-CGTGCATTCCGCTGCTGCTGGGCA-BHQ-2 This study
All blaCTX-M 
genes
U-CTX-M- FW ATYRAYACMGCVGATAAYWCGCA This study E. coli V460a (blaCTX-M-15), E. coli 
C277a (blaCTX-M-2), E. coli M26a 
(blaCTX-M-8), E. coli V404a (blaCTX-M-14)
U-CTX-M- REV CSGCAATSGGRTTRTAGTTAAC This study
U-CTX-M-P CY5.5-ATGTGCAGYACCAGTAARGTKATGGC-BHQ-3 This study
PhHV 
(internal 
control)
PhHV-267s GGGCGAATCACAGATTGAATC
[54] PhHV DNA cloned in pGEM-T-easy E. coli DH5αPhHV-337as GCGGTTCCAAACGTACCAA
PhHV-305tq Cy5.5 -TTTTATGTGTCCGCCACCATCTGGATC-BHQ-3
mcr-1-like 
genes
Mcr-1-rt-fwd ATCAGCCAAACCTATCCCATC
This study E. coli FI-4531 (mcr-1) [55], K. pneumoniae KP-6884 (mcr-1.2) [33]Mcr-1-rt-rev ACACAGGCTTTAGCACATAGC
Mcr-1-rt-p Cy5-GACAATCTCGGCTTTGTGCTGACGATC-BHQ-3
ESBL: extended-spectrum beta-lactamases.
a The amplification programme consisted of 35 two-step cycles of 15s at 95 °C and 60s at 60 °C.
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mirabilis (23.6%) and E. coli (16.1%) than among K. 
pneumoniae (9.3%), and with a higher proportion 
among isolates from inpatients (20.3%) but a remark-
able proportion (11.1%) also among those from outpa-
tients (Table 2).
The ESCR-carbaR phenotypes were mostly contributed 
by K. pneumoniae, with higher proportion among iso-
lates from inpatients (25.1% of K. pneumoniae) but also 
a notable proportion among those from outpatients 
(7.7% of K. pneumoniae) (Table 2).
Considering the nature of resistant isolates, the major-
ity of those from outpatients (n=224) were from urine 
(206/224, 91.9%), while those from inpatients (n=428) 
were from different specimens (urine: 239/428, 55.8%; 
blood: 55/428, 12.8%; respiratory tract samples: 
54/428, 12.6%).
Beta-lactamase phenotypes and genotypes of 
the ESCR and carbapenem-resistant isolates
Of the ESCR-carbaS isolates, 460 (90.5%) were ESBL-
positive and 384 of them (83.4%) carried a blaCTX-M 
ESBL gene (Figure 2 and Table 3).
Table 3
Resistance mechanisms detected in the investigated phenotypic resistant isolates by species included, nationwide 
surveillance survey, Italy, October 2013 (n=652 isolates)
Phenotypic resistance Resistance mechanism Escherichia coli Klebsiella pneumoniae Proteus mirabilis Total
N % n % n % n % 
Total 2,352 100 697 100 275 100 3,324 100 
Resistant 392 16.7 195 28.0 65 23.6 652 19.6
ESCR-carbaS Total 378 96.4 65 33.3 65 100.0 508 77.9 
ESBL
CTX-M-1 264 69.8 50 76.9 0 NA 314 61.8
CTX-M-9 61 16.1 0 NA 0 NA 61 12.0
CTX-M-1 + 9 8 2.1 1 1.5 0 NA 9 1.8
Other ESBL 28 7.4 9 13.8 39 60.0 76 15.0
ACBL
CMY/LAT/ACT/MIR 12 3.2 0 NA 24 36.9 36 7.1
DHA 0 NA 0 NA 1 1.5 1 0.2
Other Other resistance mechanism 5 1.3 5 7.7 1 1.5 11 2.1
ESCR-carbaR Total 14 3.6 130 66.7 0 0.0 144 22.1 
CARBA
KPC 2 14.3 108 83.2 0 NA 110 76.4
VIM 1 7.1 2 1.5 0 NA 3 2.1
OXA-48 2 14.3 3 2.3 0 NA 5 3.5
ESBL
CTX-M-1 4 28.6 9 6.9 0 NA 13 9.0
CTX-M-9 3 21.4 0 NA 0 NA 3 2.1
CTX-M-1 + 9 0 NA 1 0.8 0 NA 1 0.7
ACBL
CMY/LAT/ACT/MIR 2 14.3 0 NA 0 NA 2 1.4
DHA 0 NA 2 1.5 0 NA 2 1.4
Other Other resistance mechanism 0 NA 5 3.8 0 NA 5 3.5
Total Total 392 100 195 100 65 100 652 100 
CARBA
KPC 2 0.5 108 55.4 0 NA 110 16.9
VIM 1 0.3 2 1.0 0 NA 3 0.5
OXA-48 2 0.5 3 1.5 0 NA 5 0.8
ESBL
CTX-M-1 268 68.4 59 30.3 0 NA 327 50.2
CTX-M-9 64 16.3 0 NA 0 NA 64 9.8
CTX-M-1 + 9 8 2.0 2 1.0 0 NA 10 1.5
ACBL
CMY/LAT/ACT/MIR 14 3.6 0 NA 24 36.9 38 5.8
DHA 0 NA 2 1.0 1 1.5 3 0.5
Other Other resistance mechanism 33 8.4 19 9.7 40 61.5 92 14.1
ACBL: acquired class C beta-lactamase-producing; CARBA: carbapenemase-producing; CTX-M-1: CTX-M group 1 producers; CTX-M-9: CTX-M 
group 9 producers; CTX-M-1+9: CTX-M group 1 and group 9 producers; ESBL: extended-spectrum beta-lactamase-producing; ESCR-carbaR: 
non-susceptible to extended-spectrum cephalosporins and non-susceptible to carbapenems; ESCR-carbaS: non-susceptible to extended-
spectrum cephalosporins but susceptible to carbapenems; NA: not applicable.
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The proportion of blaCTX-M genes was 92.2% among 
ESBL-positive E. coli and 84.7% among ESBL-positive 
K. pneumoniae, while such genes were never detected 
among ESBL-positive isolates of P. mirabilis (Figure 2). 
Among CTX-M-positive isolates, most carried blaCTX-
M genes of group 1 (81.5%), while a minority carried 
blaCTX-M genes of group 9 (16,0%) and a small pro-
portion carried blaCTX-M genes of both CTX-M groups 
(2.5%) (Table 3). CTX-M-positive isolates were detected 
from all centers (Figure 1).
Comparison of these data with results from the earlier 
Italian nationwide survey on producing ESBL-producing 
Enterobacteriaceae, carried out in 2003 [29], revealed 
a notable increase in the proportion of ESBL-producing 
isolates (from 6.4% to 14.4%; p < 0.001, consider-
ing the three target species). Among outpatients, the 
proportion of ESBL producers increased from 3.4% to 
11.0% (p < 0.001), and the increase was especially large 
among E. coli (from 1.9% to 10.9%; p < 0.001).
The majority of the ESCR-carbaS isolates that were 
ESBL-negative were positive for an acquired ACBL gene 
(n = 37, 79%) which, in most cases, belonged to the 
CMY/LAT/ACT/MIR lineage. Most of the ACBL-positive 
isolates were P. mirabilis (Figure 2, Table 3).
Concerning the ESCR-carbaR isolates, most (81.9%) 
were positive for carbapenemase genes, including 
blaKPC- (93.2%), blaOXA-48- (4.2%), and blaVIM-
type (2.6%) carbapenemase genes. The majority of 
carbapenemase-producers were K. pneumoniae, while 
only five E. coli produced a carbapenemase (Figure 
2). Interestingly, some KPC-positive K. pneumoniae 
(KPC-KP) (6.5%) and most OXA-48-positive isolates 
also harbored a blaCTX-M gene (Table 3). The 26 
ESCR-carbaR isolates that tested negative for carbap-
enemase genes were confirmed to be carbapenemase 
non-producers by spectrophotometric assay. Most of 
these isolates carried blaCTX-M genes (65.3%) while 
a minority was positive for an ACBL gene (blaDHA or 
blaCMY/LAT/ACT/MIR), suggesting that in these cases 
the carbapenem resistance mechanism was related 
with production of an ESBL or ACBL in combination 
with reduced permeability [30].
Comparison of these data with results from the first 
Italian nationwide survey on carbapenem-resistant 
Enterobacteriaceae (CRE), carried out in 2011 [22], 
revealed an increase in the proportion of carbapenem-
resistant K. pneumoniae isolates (from 11.9% to 18.7%) 
although the difference was not statistically signifi-
cant (p = 0.5). KPC-KP remained the major contributors 
(83.1% of carbapenem-resistant K. pneumoniae in 2013 
vs. 87.2% in 2011). Among outpatients, the propor-
tion of KPC-KP increased from 2.2% in 2011 to 4.6% 
(p < 0.05).
A detailed distribution of the resistance genes in the 
Italy is reported in Figure 2, and the distribution by 
species and type of patients is reported in Table 2.
Antimicrobial susceptibility
All ESBL-producing isolates that were carbapenemase-
negative remained susceptible to imipenem and mero-
penem, while ertapenem susceptibility was 98.1% 
among E. coli and 82.2% among K. pneumoniae (Table 
4).
Among the carbapenemase producers, all were non-
susceptible to ertapenem, while most carbapene-
mase-producing E. coli were susceptible to imipenem 
Table 4
Antimicrobial susceptibility testing results for the investigated isolates, nationwide surveillance survey, Italy, October 2013 
(n=652 isolates)
Species Phenotypic resistance n
Susceptible (%)
AK GM CIP CAZ CTX FEP IMI MEM ERT AZT TRIM/SUL COLa TIGa
Escherichia coli 
ESBL 368 94.8 61.7 9.8 10.6 0.8 14.9 100.0 100.0 98.1 6.3 43.8 NA NA
CARBA 5 80.0 60.0 20.0 20.0 0.0 20.0 80.0 60.0 0.0 20.0 40.0 100.0 100.0
Others 19 100.0 89.5 52.6 0.0 0.0 94.7 100.0 100.0 89.5 5.3 42.1 NA NA
Total 392 94.9 63.0 12.0 10.2 0.8 18.9 99.7 99.5 96.4 6.4 43.6 NA NA
Klebsiella pneumoniae 
ESBL 73 91.8 39.7 21.9 4.1 6.8 6.8 100.0 100.0 82.2 8.2 26.0 NA NA
CARBA 113 16.8 48.7 0.9 0.0 0.0 0.0 3.5 3.5 0.0 0.0 25.7 61.9 94.4
Others 9 66.7 88.9 44.4 0.0 66.7 77.8 100.0 88.9 55.6 77.8 55.6 NA NA
Total 195 47.2 47.2 10.8 1.5 5.6 6.2 44.1 43.6 33.3 6.7 27.2 NA NA
Proteus mirabilis 
ESBL 39 92.3 0.0 30.8 43.6 7.7 61.5 NA 100.0 100.0 87.2 25.6 NA NA
CARBA 0 NA NA NA NA NA NA NA NA NA NA NA NA NA
Others 26 96.2 57.7 7.7 0.0 0.0 88.5 NA 100.0 100.0 100.0 7.7 NA NA
Total 65 93.8 23.1 21.5 26.2 4.6 72.3 NA 100.0 100.0 92.3 18.5 NA NA
AK: amikacin; AZT: aztreonam; CARBA: carbapenemase production; CAZ: ceftazidime; CIP: ciprofloxacin; COL: colistin ; CTX: 
ceftriaxone; ERT: ertapenem; ESBL: extended spectrum beta-lactamase production; FEP: cefepime; GM: gentamicin; IMI: 
imipenem; MEM: meropenem; NA: not applicable; TIG: tigecycline; TRIM/SUL: trimethoprim/sulfamethoxazole .
a COL and TIG were tested only for carbapenemase producers.
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and meropenem (80.0% and 60.0%, respectively). 
Carbapenemase-producing K. pneumoniae were more 
susceptible to gentamicin than to amikacin (48.7% 
vs. 16.8%). Broth microdilution assays, carried out 
with the 113 carbapenemase-producing K. pneumo-
niae, revealed that 61.7% and 94.4% were suscepti-
ble to colistin and tigecycline, respectively, while all 
five carbapenemase-producing E. coli were suscepti-
ble to both drugs (Table 4). These results were over-
all similar to those reported from the European Survey 
of Carbapenemase-Producing Enterobacteriaceae 
(EuSCAPE) survey in 2015 [31], and underscore the 
remarkable rate of colistin resistance among carbap-
enemase-producing K. pneumoniae circulating in Italy. 
No significant differences in susceptibility to these two 
drugs were detected among inpatients and outpatients 
(data not shown).
Screening for mcr-1-like genes in colistin-
resistant isolates
The 43 colistin-resistant carbapenemase-positive K. 
pneumoniae isolates were screened for the presence of 
mcr-1-like genes, encoding transferable colistin resist-
ance [32,33]. All the tested isolates yielded negative 
results, revealing that colistin resistance was caused 
by different mechanisms.
Discussion
This study provides an updated picture of the preva-
lence, distribution, beta-lactamase profiles and 
susceptibilities of ESBL-, carbapenemase- and ACBL-
producing E. coli, K. pneumoniae and P. mirabilis circu-
lating in Italy.
Compared with the earlier Italian nationwide survey 
on ESBL-producing Enterobacteriaceae, carried out 
in 2003 [29], the proportion of ESBL-producing iso-
lates (considering the three target species) showed a 
notable increase, especially among outpatients and 
among E. coli. At the level of resistance mechanisms, 
this epidemiological evolution was associated with a 
remarkable increase in the prevalence of CTX-M-type 
enzymes, which, in 2013, represented by far the most 
common type of ESBL in E. coli and in K. pneumoniae. 
Interestingly, despite their ability to spread, the genes 
encoding these resistance mechanisms have not dis-
seminated in P. mirabilis, where the ESCR phenotype 
was found to be relatively common (23.6% of iso-
lates) but due to other mechanisms, i. e. ESBLs other 
than CTX-M-type or ACBLs, mostly of the CMY/LAT/
ACT/MIR lineage. A similar epidemiological evolution 
was observed in other European Countries including 
Belgium (with 77% vs 46% of CTX-M-positive isolates, 
among ESBL-producing E. coli, in 2008 vs 2006) [34], 
Spain (with 72% vs 52% of CTX-M- positive isolates 
among ESBL-producing E. coli in 2006 vs 2000) [35].
Concerning carbapenem resistance, a notable increase 
was observed among K. pneumoniae in comparison 
with data from the first Italian nationwide survey on 
CRE, carried out in 2011 [22], with KPC-KP remaining the 
major contributors of CRE endemicity in Italy and other 
types of carbapenemases remaining uncommon. These 
findings underscore the ability of carbapenemase-pro-
ducing Enterobacteriaceae (CPE) to rapidly disseminate 
and establish conditions of high-level endemicity, and 
the notion that CPE are associated with a heightened 
epidemiological risk and deserve special attention, 
as readily acknowledged by the European Centre for 
Disease Prevention and Control (ECDC) [36]. Indeed, 
the data from the EARS-NET surveillance system indi-
cate that there is an overall increasing spread of CRE 
in some European countries [21], and results from the 
EuSCAPE project have shown that some regions are 
experiencing a worrisome prevalence of CPE per 10,000 
hospital admissions, ranging from four to six for Italy, 
Greece and Spain [37].
Interestingly, KPC-KP isolates were also found from 
outpatients, at a rate that was approximately double 
compared with that found in the 2011 survey (4.6% 
vs 2.2%) [22]. Since a significant proportion of these 
outpatients could have been recently hospitalised or 
otherwise have had contact with healthcare services, 
this figure may not reflect accurately the prevalence of 
KPC-KP in the community, in Italy. However, this find-
ing points to an increasing dissemination of CPE also 
outside the hospital setting, likely reflecting the abil-
ity of KPC-KP to establish persistent intestinal coloni-
sation even after hospital discharge [38,39]. It might 
herald a possible dissemination in the community like 
the one previously witnessed with CTX-M-producing E. 
coli [40]. Indeed, recent reports from the US and Spain 
have described the emergence of CPE infections also 
in the community, underscoring this possibility [41,42]. 
Such a scenario should be avoided, and suitable infec-
tion control measures should be enforced to address 
this phenomenon in settings of high CRE endemicity 
like Italy and some other European countries [37].
In this grim scenario, the good news was that (i) overall 
carbapenem susceptibility was retained by P. mirabi-
lis, with no carbapenemase-positive isolates detected 
in this species despite the high endemicity of CPE; and 
that (ii) no mcr-1-like transferable colistin resistance 
genes were detected among the colistin-resistant CPE 
isolates, suggesting that this worrisome resistance 
mechanism remains uncommon among colistin-resist-
ant CPE circulating in Italy.
Updated molecular surveillance data on resistance 
genes to beta-lactams are of increasing importance 
due to the introduction on the market of new antibiot-
ics for resistant Gram-negatives that are based on new 
beta-lactamase inhibitors (e. g. avibactam), which will 
be useful for treatment of infections caused by ESBL 
and carbapenemase producers [43]. The new inhibitors, 
however, are not active against all beta-lactamases e. 
g. avibactam is able to inhibit class A but not class B 
beta-lactamases. Thus the possibility of using these 
new drugs will depend on the specific mechanism 
of resistance, and rapid testing for these resistance 
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mechanisms will become an essential step in antibiotic 
stewardship programs. In this perspective, this survey 
underscores the major role of beta-lactamase genes 
as resistance determinants in Enterobacteriaceae in 
the Italian epidemiological setting, and provides rel-
evant information for the selection of the most suitable 
diagnostic strategies based on molecular detection of 
beta-lactam resistance mechanisms. A limitation of 
this study is that, due to the study design, laboratory-
based surveillance, information about risk factors for 
developing antibiotic resistance was not available. 
Future studies are warranted to investigate these 
aspects, which are relevant to understand the reasons 
for the epidemiological differences observed in differ-
ent European countries and to contextualise infection 
control policies.
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